• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2

tetano

Editor, Senior Moderator
Cell Rep Med


. 2022 Aug 29;100743.
doi: 10.1016/j.xcrm.2022.100743. Online ahead of print.
Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2


Jasper Fuk-Woo Chan[SUP] 1 [/SUP], Bingjie Hu[SUP] 2 [/SUP], Yue Chai[SUP] 2 [/SUP], Huiping Shuai[SUP] 2 [/SUP], Huan Liu[SUP] 2 [/SUP], Jialu Shi[SUP] 2 [/SUP], Yuanchen Liu[SUP] 2 [/SUP], Chaemin Yoon[SUP] 2 [/SUP], Jinjin Zhang[SUP] 2 [/SUP], Jing-Chu Hu[SUP] 3 [/SUP], Yuxin Hou[SUP] 2 [/SUP], Xiner Huang[SUP] 2 [/SUP], Terrence Tsz-Tai Yuen[SUP] 2 [/SUP], Tianrenzheng Zhu[SUP] 2 [/SUP], Wenjun Li[SUP] 3 [/SUP], Jian-Piao Cai[SUP] 2 [/SUP], Cuiting Luo[SUP] 2 [/SUP], Cyril Chik-Yan Yip[SUP] 4 [/SUP], Anna Jinxia Zhang[SUP] 5 [/SUP], Jie Zhou[SUP] 5 [/SUP], Shuofeng Yuan[SUP] 6 [/SUP], Bao-Zhong Zhang[SUP] 3 [/SUP], Jian-Dong Huang[SUP] 7 [/SUP], Kelvin Kai-Wang To[SUP] 8 [/SUP], Kwok-Yung Yuen[SUP] 1 [/SUP], Hin Chu[SUP] 9 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 was a dominant circulating SARS-CoV-2 variant worldwide. Recent reports hint that BA.2 is similarly potent regarding antibody evasion but may be more transmissible than BA.1. The pathogenicity of BA.2 remains unclear and is of critical public health significance. Here we investigated the virological features and pathogenicity of BA.2 with in vitro and in vivo models. We show that BA.2 is less dependent on transmembrane protease serine 2 (TMPRSS2) for virus entry in comparison with BA.1 in vitro. In K18-hACE2 mice, BA.2 replicates more efficiently than BA.1 in the nasal turbinates and replicates marginally less efficiently in the lungs, leading to decreased body weight loss and improved survival. Our study indicates that BA.2 is similarly attenuated in lungs compared with BA.1 but is potentially more transmissible because of its better replication at the nasal turbinates.

Keywords: BA.1; BA.2; COVID-19; Omicron; SARS-CoV-2; TMPRSS2; pathogenicity; replication.
 
Back
Top Bottom